FORA Capital LLC Has $1.67 Million Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

FORA Capital LLC lifted its position in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 50.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 9,060 shares of the medical research company's stock after purchasing an additional 3,034 shares during the quarter. FORA Capital LLC's holdings in Charles River Laboratories International were worth $1,672,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Pinnacle Bancorp Inc. boosted its stake in shares of Charles River Laboratories International by 52.0% in the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock valued at $35,000 after purchasing an additional 65 shares during the period. Optiver Holding B.V. acquired a new position in Charles River Laboratories International in the 4th quarter valued at $37,000. GeoWealth Management LLC boosted its position in shares of Charles River Laboratories International by 311.5% during the 4th quarter. GeoWealth Management LLC now owns 251 shares of the medical research company's stock worth $46,000 after purchasing an additional 190 shares in the last quarter. Pilgrim Partners Asia Pte Ltd purchased a new stake in shares of Charles River Laboratories International during the 4th quarter worth $48,000. Finally, Tortoise Investment Management LLC grew its stake in Charles River Laboratories International by 77.7% in the 4th quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company's stock valued at $49,000 after acquiring an additional 115 shares during the last quarter. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have issued reports on CRL. UBS Group reaffirmed a "neutral" rating and set a $185.00 price target (down from $250.00) on shares of Charles River Laboratories International in a research note on Friday, January 17th. Citigroup raised shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and raised their price target for the stock from $155.00 to $175.00 in a research note on Tuesday, March 4th. William Blair cut shares of Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a research note on Wednesday, January 22nd. Morgan Stanley decreased their price target on shares of Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating on the stock in a research note on Wednesday, February 5th. Finally, Mizuho decreased their price target on shares of Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 9th. One investment analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and one has given a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Hold" and an average price target of $176.00.

Charles River Laboratories International Trading Down 1.8%

NYSE CRL traded down $2.52 during mid-day trading on Friday, hitting $138.84. The company's stock had a trading volume of 920,260 shares, compared to its average volume of 966,631. Charles River Laboratories International, Inc. has a 52-week low of $91.86 and a 52-week high of $254.15. The stock's fifty day simple moving average is $138.40 and its two-hundred day simple moving average is $166.20. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. The firm has a market capitalization of $6.82 billion, a P/E ratio of 925.60, a price-to-earnings-growth ratio of 4.54 and a beta of 1.50.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The medical research company reported $2.34 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.06 by $0.28. The company had revenue of $984.17 million for the quarter, compared to analyst estimates of $942.34 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The business's quarterly revenue was down 2.7% on a year-over-year basis. During the same quarter last year, the firm posted $2.27 earnings per share. Research analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Insider Activity

In related news, CEO James C. Foster acquired 6,075 shares of the business's stock in a transaction on Thursday, February 20th. The shares were purchased at an average price of $165.01 per share, for a total transaction of $1,002,435.75. Following the acquisition, the chief executive officer now owns 183,639 shares in the company, valued at approximately $30,302,271.39. This represents a 3.42% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Birgit Girshick bought 1,514 shares of the stock in a transaction on Thursday, February 20th. The shares were acquired at an average cost of $164.63 per share, for a total transaction of $249,249.82. Following the purchase, the chief operating officer now owns 55,058 shares in the company, valued at approximately $9,064,198.54. This represents a 2.83% increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 1.30% of the company's stock.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).